TW432062B - Compounds useful as antiproliferative agents and garet inhibitors - Google Patents
Compounds useful as antiproliferative agents and garet inhibitors Download PDFInfo
- Publication number
- TW432062B TW432062B TW085101051A TW85101051A TW432062B TW 432062 B TW432062 B TW 432062B TW 085101051 A TW085101051 A TW 085101051A TW 85101051 A TW85101051 A TW 85101051A TW 432062 B TW432062 B TW 432062B
- Authority
- TW
- Taiwan
- Prior art keywords
- electrochromic
- substrate
- group
- unsubstituted
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000758 substrate Substances 0.000 claims description 36
- 239000011521 glass Substances 0.000 claims description 30
- 239000003792 electrolyte Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 12
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 229910000314 transition metal oxide Inorganic materials 0.000 claims description 6
- 238000003487 electrochemical reaction Methods 0.000 claims description 5
- -1 polyethylene terephthalate Polymers 0.000 claims description 5
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 4
- 239000005751 Copper oxide Substances 0.000 claims description 4
- 229910000431 copper oxide Inorganic materials 0.000 claims description 4
- 230000002687 intercalation Effects 0.000 claims description 4
- 238000009830 intercalation Methods 0.000 claims description 4
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims description 4
- 229910001930 tungsten oxide Inorganic materials 0.000 claims description 4
- 239000002033 PVDF binder Substances 0.000 claims description 3
- 229910000449 hafnium oxide Inorganic materials 0.000 claims description 3
- 229920000767 polyaniline Polymers 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 3
- 229910001887 tin oxide Inorganic materials 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229920001940 conductive polymer Polymers 0.000 claims description 2
- WIHZLLGSGQNAGK-UHFFFAOYSA-N hafnium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Hf+4] WIHZLLGSGQNAGK-UHFFFAOYSA-N 0.000 claims description 2
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical group [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 229910021392 nanocarbon Inorganic materials 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims 4
- 229910000480 nickel oxide Inorganic materials 0.000 claims 3
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 claims 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 claims 1
- 101100162703 Caenorhabditis elegans ani-1 gene Proteins 0.000 claims 1
- 229910016553 CuOx Inorganic materials 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- XHCLAFWTIXFWPH-UHFFFAOYSA-N [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] XHCLAFWTIXFWPH-UHFFFAOYSA-N 0.000 claims 1
- 239000003575 carbonaceous material Substances 0.000 claims 1
- 229940099990 ogen Drugs 0.000 claims 1
- 229910001935 vanadium oxide Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 239000003944 phosphoribosylglycinamide formyltransferase inhibitor Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000004040 coloring Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000009413 insulation Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 206010039203 Road traffic accident Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 229910005855 NiOx Inorganic materials 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229910001195 gallium oxide Inorganic materials 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000011244 liquid electrolyte Substances 0.000 description 1
- 239000005344 low-emissivity glass Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
M432062 五、新型說明: 【新型所屬之技術領域】 [0001] 本創作係有關於一種電致變色元件,尤指一種可縮 短電致變色層之氧化或還原反應時間,以改善現有電致 變色結構因變色之切換速度過慢而導致使用上不甚方便 之電致變色元件。 【先前技術】 [0002] 按,後視鏡是汽車上不可缺少的安全配件,它能讓 0 駕駛者不需回頭就能方便地看到後面的交通狀況;一般 後視鏡可分為車内後視鏡與車外左右側後視鏡,行車時 雖可藉由後視鏡避免因轉頭而造成交通事故的風險;.然 ,當駕駛者於夜間行車時,若後方車輛以遠光燈或強光 照射,造成後視鏡反射到駕駛者的眼睛上而產生眩光, 瞬間將使得駕駛者眼前一片漆黑,此時前方若有來車急 停或行人衝出將容易造成重大的交通事故;再者,駕駛 者的眼睛若長期處於強光照射下亦容易產生疲勞,不只 Φ 是影響駕駛者的健康,更加容易造成交通事故的發生率 〇 [0003] 此外,在一個封閉的空間内,玻璃窗材.能夠帶給人 較寬視野的舒適感受,所以在一般建築設計上,都可以 看到許多玻璃窗材的應用;然,增加窗戶的設置面積以 達到大量採光的方式,卻也使得更多的太陽熱能隨之進 入封閉空間内,而增加了空調能源的消耗;目前,一般 隔絕太陽熱能的方式,會使用窗簾、低輻射玻璃(L 0 w_ E)或於玻璃外粘貼有色隔熱紙等;以裝設窗簾為 10120360#早編號删1 第 3 頁 / 共 19 頁 1012011505-0 M432062 \ 例,其不但安裝繁瑣'佔用室内空間外,又常有地形上 的限制(例如:八角玻璃)而無法安裝,且曰後清理又 有廉布拆卸與安裝的麻煩;而採用低輻射玻璃的話,其 產品本身除了具有多層鍍膜製程繁雜的缺點外,在需要 紅外線進入室内保暖的狀態下,低輻射玻璃又因為無調 光功能而無法應用之,且雖然可以阻擋紅外線,但節能 效果有限;而黏貼隔熱紙雖能使得陽光照射的部份不那 麼刺眼,但對於隔熱作用卻是差強人意,且使用後常發 生氧化、顏色不均、褪色、起泡及皺褶等問題瑕疵,若 使用顏色較深之隔熱紙時,雖具較佳之隔熱效果,但於 陰、雨天時,也會因為隔熱紙而使得玻璃透光不佳,導 致室内採光不足等缺失。
L0004J 於是,為克服上述缺失,近年來業界即研發出一種 電致變色玻璃’又稱調光玻璃,其可藉由改變電麼與電 流以調整玻璃可見光與紅外線的透光率,實現隨意變換 玻璃透光度之效果’除了可作為抗眩後視鏡與節能窗使 用外’更可應用於功能型眼鏡與汽車天窗等需調整光線 強弱之用途上;請參閱第四圖所示,其為現有電致變色 玻璃結構之剖面圖,包括有-第-透明玻璃(7丄)、 一第二透明玻璃(81)第—透明導電薄膜(72 )和一第二透明導電薄膜(82),分別位於第一透明 玻璃(7 1 )和第二透明玻璃(8丄)上,材料可為氧 化钢錫(IT0); 一第一電致變色層(73)和一第 二電致變色層(83),分別位於第—透明導電薄膜( 7 2)和第二透明導電薄膜(8 2)上;一電解質層( 1〇_产單編號Aoli1 ) ’位於第一第電/^ ^=73)和第二電致變色 101201 M432062 層(8 3)之間,可為固態或液態之電解質;並在第一 透明導電薄膜(72)和第二透明導電薄膜(82)之 間提供一外接電壓,例如一直流電池;藉著調整電壓或 電流大小,使電致變色層中之材料產生電化學反應,其 產物對特定波長的光具有不同程度的吸收度,而表現出 不同的顏色。 [0005] 藉由上述之電致變色玻璃於實際實施時雖可解決汽 車後視鏡以及玻璃窗材上應用的缺失,然,當電致變色 玻璃之面積越大時,其整片玻璃變色的時間亦成正相關 地增加,對於一些需立即變色的場合(例如:後視鏡被 強光照射或配戴調光玻璃的眼鏡於戶外走進室内時), 常造成變色之切換速度過慢而導致使用上不甚方便的麻 煩。 【新型内容】 [0006] 緣是,創作人有鑑於此,秉持多年該相關行業之豐 富設計開發及實際製作經驗,改良創作一電致變色元件 ,其目的在於提供一種可縮短電致變色層之氧化或還原 反應時間,以改善現有電致變色結構因變色之切換速度 過慢而導致使用上不甚方便之電致變色元件。 [0007] 為了達到上述實施目的,本創作人乃研擬如下實施 技術,係主要包含有一由第一基板以及設於第一基板上 之第一透明電極層所組成之第一模組、一由第二基板以 及設於第二基板上之第二透明電極層所組成之第二模組 ;其中,第二透明電極層係面對第一透明電極層;再於 第一透明電極層與第二透明電極層之間設有一用以提供 1012011505-0 10120360^單編號A〇101 第5頁/共19頁 M432062 陽離子參與電化學反應之電解質層,且電解質層與第一 透明電極層之間設有一第一電致變色層;其中,第一電 致變色層由複數個第一顯示單元所組成,於兩個第一顯 示單元間具有一間隙,使得每一個第一顯示單元係彼此 不相連接。 [0008] 藉此,當第一透明電極層和第二透明電極層之間外 接電壓時,第一顯示單元可視為彼此並聯之狀態,使得 橫跨第一顯示單元之電壓均相同,導致第一顯示單元發 生氧化或還原反應之開始時間皆相同,避免因電致變色 元件面積過大而增加反應完成時間之缺失,使得整個第 一電致變色層完成著色或去色時間可大幅縮短,達到於 A3 (2 9 〇mmx4 2 Omm)面積大小之電致變色元 件,其著色或去色之完成時間約為3 0秒。 [0009] 此外,電解質層與第二透明電極層之間可進一步設 有一第二電致變色層,且第二電致變色層係由複數個第 二顯示單元所組成,第二顯示單元間彼此具有一間隙, 使得第二顯示單元係彼此不相連接;藉此,不僅可縮短 第二電致變色層之氡化或還原反應時間,亦能使得電致 變色元件之變色效果由一種顏色(例如:深藍色)變成 另一種顏色(例如:深標色)。 【實施方式】 [0010] 本創作之目的及其結構功能上的優點,將依據以下 圖面所示之結構,配合具體實施例予以說明,俾使審查 委員能對本創作有更深入且具體之瞭解。 首先,請參閱第一圖所示,為本創作電致變色元件 證0360#單編號A〇101 第6頁/共19頁 1012011505-0 其-較佳實施例之剖面圖,其主要包含有: —第一模組⑴,係由-第-基板(11)以及 設於第-基板(1i)上之第_透明電極層(i 組成; 4 —第二模組(2),係由-第二基板(2 1 )以及 。又於第-基板(2 1 )上之第二透明電極層(2 2)所 組成’第二透明電極層(2 2)係面對第-透明電極詹 (12);其中,第-基板(11)與第二基板(21 )可為選自可撓性軟性基板(例如:聚碳酸酯(p C) 基板、聚對苯二甲酸乙二g旨(p E T )基板聚甲基丙 烯酸甲酯(p〇lymethyi methacry 1 a t e,PMMA)基板、聚偏二氟乙烯(p 〇丄y
Vlnylidene diflu〇ride,pV DF)基板'聚氯乙烯(p〇lyvinyl chl 0 r i d e ’ PVC)基板以及聚氧化乙烯(p〇丄y ethylene 〇Xide,PE〇)基板等)及 玻璃基板其中之一者;而第一透明電極層(1 2)與第 —透明電極層(22)之材質可為氧化銦錫(j τ〇) '摻氟氧化錫(FTO)、鋁/氧化鋅(AZ〇)、鎵 /氧化鋅(GZO) '奈米碳材料、導電高分子以及導 電金屬等材質者; -電解質層(3),設於第—透明電極層(12) 與第二透明電極層(2 2)之間,電解質層(3)係提 供陽離子參與電化學反應;其中,陽離子係為丨A族金 屬離子(例如:H+、Li +、Na +、K、);J^ 10120360#單編號 A01〇l 一第一電致變色層(4),係設於電解質層(3) 1012011505-0 第7買/共19頁 與第一透明電極層(i 2)之間;其中,第一電致變色 層(4)由複數個第一顯示單元(4丄)所組成,第一 顯示單元(4 1)間彼此具有一間隙(5),使得該等 第一顯示單元(41 )係不相連接;其中,第一電致變 色層(4)之材質可為選自過渡金屬氧化物(例如:氧 匕鎢(W〇3)、氡化鎳(Ni〇x) '氧化鈒(、〇 5)或氧化銅(Cu〇x)#)、價間嵌入化合物(例如 •亞鐵氰化鐵(F e 4〔 F e (CN) 6〕3 )),以及 有機化合物(聚苯胺(P〇ly(aniline)) 、紫菁(viol〇gen)等)所構成之群組。 根據上述之電致變色元件於實施使用時,請參閲第 一圖所示,首先,本實施例之第一電致變色層(4 )材質係選自氧化鶴(W〇3),而電解質層(3)係以 提供L i +陽離子參與電化學反應,且第—電致變色層( 4)係由3個第一顯示單元(4 χ )所組成;接著,於 第一透明電極層(12)和第二透明電極層(22)之 間提供一外接電壓,此時,L 土 +陽離子和電子e _同時 進入第-電致變色層(4)中,使第一電致變色層(4 )之氧化鶴發生還原反應而形成深藍色之還原態l i xW (1 X ) WV x 0 3,此即為著色反應,其反應化學式 如下: W03+x(Li++e-)-.Li w W 〇 - X IVO-X) Vxv3, 由於第-電致變色層(4)係由3個第一顯示單元(4 ^所組成,且彼此間具有—間隙(5),故當第—透 明電極層(1 2 )和第二透明電極層(2 2)之間外接 電麼時’ 3個第—顯示單元(4 i )可視為彼此並聯之 101咖产單编號_1 第8頁/共19頁 1012011505-0 料:12062 狀態,使得横跨3個第一顧一 〇㈣顯不早几(4 1)之電屡均相 问,導致3個第一顯示單无r/ Ί、 (41)發生還原反應之開 時^㈣,使得整料—概變色層(4)完成著 色時間可縮短;可預期的,♦ 贫 _ 頂摘w第一電致變色層(4 )的 早7° (4 1 )越多時,其著色反應時間將越短 ’值:注意的,前述第-電致變色層(4)由3個第一 j不早π ( 4 1 )所組祕對本創作其—較佳實施例的 。兄明’並不限制為3個,本創作之原則可用於2個以上 之第一顯示單元(41),在閱讀及了解本創作的敎導 後,相關之變化實施屬於業界技能;而本創作經實驗證 實’可於A 3 ( 2 9 0mmX4 2 Omm)面積大小之電 致支色70件’將著色完成時間大幅縮短至約為3 〇秒或 是更短的時間。 而當移除外接電壓或當外接電壓極性轉換時,L i + 陽離子和電子e—同時離開第一電致變色層(4)中,使 第一電致變色層(4)之L i w 说 ^ ^ ιν (i-x) WVx〇3 發生氧化反應而形成透明之氧化鎢氧化態,此即為去色 反應,其反應化學式如下:
LixWiv(i-x)WVx°3^W03^(Li++e-); 同理,由於第一電致變色層(4)係由3個第一顯示單 元(41 )所組成,導致3個第一顯示單元(4 1)發 生氧化反應之開始時間皆相同,使得整個第—電致變色 層(4)完成去色之時間可縮短。 請參閱第三圖所示,為本創作電致變色元件其二較 佳實施例之剖面圖’大致與前述之第一較佳實施例相同 ,其不同之處在於電解質層(3)與第二选明電極層( 10120咖^單編號 A0101 第9頁/共19頁 1012011505-0 M432062 22)之間係進一步設有一第二電致變色層(6),且 第二電致變色層(6 )係由複數個第二顯示單元(6 1 )所組成,第二顯示單元(6 1 )間彼此具有一間隙( 5),使得第二顯示單元(61)係彼此不相連接;其 中,第二電致變色層(6)之材質係為選自過渡金屬氧 化物(例如:氣化鑛、氧化鎮、氧化鈒、氧化銅等)、 價間嵌入化合物(例如:亞鐵氰化鐵)以及有機化合物 (例如:聚笨胺、紫菁等)所構成之群組。 根據上述之電致變色元件其二較佳實施例於實施使 用時,由於多增設一第二電致變色層(6),使得電致 變色元件可從其一較佳實施例之透明與深藍色間之轉換 ,變成深藍色與另一種顏色間之轉換,以配合使用上之 需求;而第二電致變色層(6)之第二顯示單元(6 1 )因外加電壓所作動的方式與使用的功效皆與其一較佳 實施例相同,於此不再贅述。 由上述之實施說明可知,本創作與現有技術相較之 下,本創作藉由將電致變色層分別分割為複數個顯示單 元,使得顯示單元於第一、二透明電極層外接電壓時, 顯示單元可視為彼此並聯之狀態,使得橫跨於顯示單元 之電壓均相同,導致顯示單元發生還原或氧化反應之開 始時間皆相同,避免因電致變色元件面積過大而增加反 應完成時間之缺失,使得整個電致變色層完成著色或去 色之時間可大幅縮短,達到於A 3面積大小之電致變色 元件,其反應完成時間約為3 0秒之功效;藉此,改善 現有電致變色結構對於一些需立即變色的場所(例如: 後視鏡被強光照射或配戴調光玻璃的眼鏡於戶外走進室 10120360#單编號 A0101 第10頁/共19頁 1012011505-0 M432062 内時),常造成變色之切換速度過慢而導致使用上不甚 方便的麻煩。 綜上所述,本創作之電致變色元件,的確能藉由上 述所揭露之實施例,達到所預期之使用功效,且本創作 亦未曾公開於申請前,誠已完全符合專利法之規定與要 求。爰依法提出新型專利之申請,懇請惠予審查,並賜 准專利,則實感德便。
惟,上述所揭之圖示及說明,僅為本創作之較佳實 施例,非為限定本創作之保護範圍;大凡熟悉該項技藝 之人士,其所依本創作之特徵範疇,所作之其它等效變 化或修飾,皆應視為不脫離本創作之設計範疇。 【圖式簡單說明】 [0011] 第一圖:本創作其一較佳實施例之剖面圖 [0012] 第二圖:本創作其一較佳實施例之平面俯視圖 [0013] 第三圖:本創作其二較佳實施例之剖面圖 [0014] 第四圖:現有電致變色玻璃結構之剖面圖 【主要元件符號說明】 [0015] 〈本創作〉 [0016] ( 1 ) [0017] (12) [0018] (21) [⑻ 19] ( 3 ) [0020] (41) 1〇1腿#單職A〇m 第一模組 (11) 第一透明電極層 (2) 第二基板 (22) 電解質層 (4) 第一顯示單元 (5) 第11頁/共19頁 第一基板 第二模組 第二透明電極層 第一電致變色層 間隙 1012011505-0 M432062 [0021] (6 ) 第二電致變色層 [0022] 〈現有〉 [0023] (71) 第 一透明玻璃 [0024] (72) 第 一透明導電薄膜 [0025] (73) 第 一電致變色層 [0026] (91) 電解質層 (6 1 )第二顯示單元 (8 1 )第二透明玻璃 (82)第二透明導電薄膜 (8 3)第二電致變色層 1〇12〇36(/單編號删1 第12頁/共19頁 1012011505-0
Claims (1)
- M432062 •、申請專利範圍: 1 . 一種電致變色元件,其包括有: 一第一模組,係由一第一基板以及設於該第一基板上 之第一透明電極層所組成; 一第二模組,係由一第二基板以及設於該第二基板上 之第二透明電極層所組成,該第二透明電極層係面對該第 一透明電極層;一電解質層,設於該第一透明電極層與該第二透明電 極層之間,該電解質層係提供陽離子參與電化學反應;以 及 一第一電致變色層,係設於該電解質層與該第一透明 電極層之間;其中,該第一電致變色層由複數個第一顯示 單元所組成,該第一顯示單元間彼此具有一間隙,使得該 等第一顯示單元係不相連接。 2 .如申請專利範圍第1項所述之電致變色元件,其中於該電 解質層與該第二透明電極層之間進一步設有一第二電致變 色層,該第二電致變色層係由複數個第二顯示單元所組成 ,該第二顯示單元間彼此具有一間隙,使得該等第二顯示 單元係不相連接。 3.如申請專利範圍第2項所述之電致變色元件,其中該第二 電致變色層之材質係選自過渡金屬氧化物、價間嵌入化合 物以及有機化合物所構成之群組。 4 .如申請專利範圍第3項所述之電致變色元件,其中該過渡 金屬氧化物係選自氧化鎢(W〇3)、氧化鎳(Ni〇x )、氧化釩(V。0c )和氧化銅(C u 0 )所構成之 2 5 X 群組。 1012011505-0 10120360^«^ A〇101 ^ 13 1 / ^ 19 1 M432062 .如申請專利範圍第3項所述之電致變色元件,其中該價間 嵌入化合物係為亞鐵氰化鐵(F e 〔 F e (CN)貝曰 3) 。 4 6J 6.如申請專利範圍第3項所述之電致變色元件,其中該有機 化合物係為聚苯胺(P〇 1 y (a n i 1 i n e/)或紫 菁(v i ο 1 〇 g e n)其中之一。 7 .如申請專利範圍第1項所述之電致變色元件其中該第— 基板與該第二基板係為選自可撓性軟性基板或玻璃基板其 中之一者。8.如申請專利範圍第7項所述之電致變色元件,其中該可撓 性軟性基板係選自聚碳酸酯(PC)基板、聚對笨二甲酸 乙二醋(P E T)基板、聚甲基丙稀酸甲_ (p〇 i ethyl me t h a c r y i a t e,PMMA)基 板、聚偏二氟乙稀(P〇lyvinyl idene j i f lU〇r ide,PVDF)基板、聚氣乙烯(p〇 lyvinyl chloride,PVC)基板以及 聚氧化乙烯(polyethylene oxide, P E 0)基板所構成之群組。 9 .如申請專利範圍第1項所述之電致變色元件,其中該第一 透明電極層與該第二透明電極層之材質係分別選自氧化銦 錫(ITO)、摻氟氧化錫(FTO)、鋁/氧化鋅(A Z0)、嫁/氧化辞(GZO)、奈米碳材料、導電高分 子以及導電金屬所構成之群組。 10 .如申請專利範圍第1項所述之電致變色元件,其中該第一 電致變色層之材質係選自過渡金屬氧化物、價間叙入化合 物以及有機化合物所構成之群組。 1012011505-0 10120360#單編號A01〇l 第14頁/共19頁 1 料·62 U .如申請專利範圍第10項所述之電致變色元件其中該過渡 金屬氧化物係選自氧化鎢(W03) '氧化鎳(Ni0 )、氧化鈒(V2〇5)和氧化銅(Cu〇x)所構成之X 群組。 12 .如申請專利範圍第10項所述之電致變色元件,其中該價間 嵌入化合物係為亞鐵氰化鐵(Fe4〔Fe(CN)〕 6 - 3)〇 • 13 .如申請專利範圍第10項所述之電致變色元件,其中該有機 ^ 化合物係為聚笨胺(Poly(aniline))或紫· 菁(vi ο 1 ogen)其中之一。 .如申請專利範圍第1項所述之電致變色元件,其中該陽離 子係為I A族金屬離子。 10120360#單編號 A〇l〇l 第15頁/共19頁 1012011505-0
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/281,639 US5608082A (en) | 1994-07-28 | 1994-07-28 | Compounds useful as antiproliferative agents and GARFT inhibitors |
PCT/US1995/009519 WO1996003406A1 (en) | 1994-07-28 | 1995-07-28 | Compounds useful as antiproliferative agents and garft inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
TW432062B true TW432062B (en) | 2001-05-01 |
Family
ID=23078167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085101051A TW432062B (en) | 1994-07-28 | 1996-01-29 | Compounds useful as antiproliferative agents and garet inhibitors |
Country Status (20)
Country | Link |
---|---|
US (2) | US5608082A (zh) |
EP (1) | EP0773943B1 (zh) |
JP (1) | JPH10503762A (zh) |
KR (1) | KR100380610B1 (zh) |
CN (2) | CN1091770C (zh) |
AT (1) | ATE206122T1 (zh) |
AU (1) | AU697138B2 (zh) |
CA (1) | CA2195420A1 (zh) |
DE (1) | DE69522945T2 (zh) |
DK (1) | DK0773943T3 (zh) |
ES (1) | ES2162933T3 (zh) |
FI (1) | FI112079B (zh) |
MX (1) | MX9700675A (zh) |
NO (1) | NO308248B1 (zh) |
NZ (1) | NZ290703A (zh) |
PT (1) | PT773943E (zh) |
RU (1) | RU2152945C2 (zh) |
SI (1) | SI0773943T1 (zh) |
TW (1) | TW432062B (zh) |
WO (1) | WO1996003406A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831100A (en) * | 1995-06-07 | 1998-11-03 | Agouron Pharmaceuticals, Inc. | Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates |
WO2001016121A1 (en) * | 1999-08-31 | 2001-03-08 | Merck & Co., Inc. | Heterocyclic compounds and methods of use thereof |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
AU2002306413A1 (en) * | 2001-02-16 | 2002-10-15 | Eli Lilly And Company | Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections |
US6962922B2 (en) * | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
WO2003033478A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
WO2003033477A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor |
US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
US6894057B2 (en) * | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
AU2003249505A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
WO2004113337A1 (en) * | 2003-06-25 | 2004-12-29 | Pfizer Inc. | Convergent synthesis of a garft inhibitor containing a methyl substitute thiophene core and a tetrahydropyrido`2,3-d! pyrimidine ring system and intermediates therefor |
WO2004113328A1 (en) * | 2003-06-25 | 2004-12-29 | Pfizer Inc. | Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
MY164457A (en) | 2005-09-07 | 2017-12-15 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
RS20080525A (en) | 2006-05-09 | 2009-09-08 | Pfizer Products Inc., | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
US8252804B2 (en) * | 2008-10-01 | 2012-08-28 | Duquesne University Of The Holy Spirit | Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same |
ES2594409T3 (es) | 2011-02-23 | 2016-12-20 | Lupin Limited | Derivados de heteroarilo como moduladores del nAChR á7 |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
WO2013005153A1 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Biaryl derivatives as nachr modulators |
US20140309275A1 (en) * | 2011-09-29 | 2014-10-16 | Emory University | Sphingosine Analogs, Compositions, and Methods Related Thereto |
IN2014MN01756A (zh) | 2012-03-06 | 2015-07-03 | Lupin Ltd | |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
CN115634228B (zh) * | 2021-07-20 | 2024-03-19 | 首都医科大学 | 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT376436B (de) * | 1982-11-05 | 1984-11-26 | Laevosan Gmbh & Co Kg | Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon |
US4927828A (en) * | 1985-03-08 | 1990-05-22 | The Trustees Of Princeton University | Diastereoisomeric tetrahydropyrido-(2,3,d) pyrimidine derivatives |
US4684653A (en) * | 1985-03-08 | 1987-08-04 | The Trustees Of Princeton University | Pyrido(2,3-d)pyrimidine derivatives |
US5026851A (en) * | 1985-03-08 | 1991-06-25 | The Trustees Of Princeton University | Pyrido[2,3-]pyrimidine derivatives |
US4831037A (en) * | 1987-04-20 | 1989-05-16 | The Trustees Of Princeton University | 4 (3H)-oxo-5,6,7,8-tetrahydropyrido-(2,3-d)pyrimidine derivatives |
US4988813A (en) * | 1986-10-20 | 1991-01-29 | The Trustees Of Princeton University | Process for the preparation of fused pyridine compounds |
US4895946A (en) * | 1987-10-26 | 1990-01-23 | The Trustees Of Princeton University | Process for the preparation of fused pyridine compounds |
US4889859A (en) * | 1988-02-05 | 1989-12-26 | The Trustees Of Princeton University | Pyrido[2,3-d]pyrimidine derivatives |
US4882333A (en) * | 1988-05-25 | 1989-11-21 | The Trustess Of Princeton University | N-(5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives |
US4882334A (en) * | 1988-05-25 | 1989-11-21 | The Trustees Of Princeton University | N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives |
DK172753B1 (da) * | 1988-05-25 | 1999-06-28 | Lilly Co Eli | N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat |
US4871746A (en) * | 1988-05-31 | 1989-10-03 | The Trustees Of Princeton University | N-[N-(tetrahydropyrido[2,3-D]pyrimidinylmethyl)-aminomethylbenzoyl]glutamic acid derivatives as neoplastic growth inhibitors |
US4883799A (en) * | 1988-06-29 | 1989-11-28 | The Trustees Of Princeton University | N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives |
EP0438261A3 (en) * | 1990-01-16 | 1992-02-26 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic glutamic acid derivatives, their production and use |
IL99500A0 (en) * | 1990-09-17 | 1992-08-18 | Agouron Pharma | Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same |
US5217974A (en) * | 1991-03-29 | 1993-06-08 | Eli Lilly And Company | Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity |
US5223503A (en) * | 1991-04-29 | 1993-06-29 | Eli Lilly And Company | 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents |
US5969136A (en) * | 1992-10-15 | 1999-10-19 | Eli Lilly And Company | Cyclization for preparing antifolate compounds |
CA2151588C (en) * | 1992-12-16 | 2002-03-19 | Michael D. Varney | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone |
-
1994
- 1994-07-28 US US08/281,639 patent/US5608082A/en not_active Expired - Fee Related
-
1995
- 1995-06-06 US US08/467,945 patent/US5646141A/en not_active Expired - Fee Related
- 1995-07-28 CA CA002195420A patent/CA2195420A1/en not_active Abandoned
- 1995-07-28 AT AT95927503T patent/ATE206122T1/de not_active IP Right Cessation
- 1995-07-28 NZ NZ290703A patent/NZ290703A/en unknown
- 1995-07-28 MX MX9700675A patent/MX9700675A/es not_active IP Right Cessation
- 1995-07-28 AU AU31517/95A patent/AU697138B2/en not_active Ceased
- 1995-07-28 JP JP8505975A patent/JPH10503762A/ja not_active Withdrawn
- 1995-07-28 DE DE69522945T patent/DE69522945T2/de not_active Expired - Fee Related
- 1995-07-28 CN CN95194376A patent/CN1091770C/zh not_active Expired - Fee Related
- 1995-07-28 PT PT95927503T patent/PT773943E/pt unknown
- 1995-07-28 SI SI9530534T patent/SI0773943T1/xx unknown
- 1995-07-28 ES ES95927503T patent/ES2162933T3/es not_active Expired - Lifetime
- 1995-07-28 KR KR1019970700588A patent/KR100380610B1/ko not_active IP Right Cessation
- 1995-07-28 DK DK95927503T patent/DK0773943T3/da active
- 1995-07-28 EP EP95927503A patent/EP0773943B1/en not_active Expired - Lifetime
- 1995-07-28 RU RU97103518/04A patent/RU2152945C2/ru not_active IP Right Cessation
- 1995-07-28 WO PCT/US1995/009519 patent/WO1996003406A1/en active IP Right Grant
-
1996
- 1996-01-29 TW TW085101051A patent/TW432062B/zh not_active IP Right Cessation
-
1997
- 1997-01-24 FI FI970317A patent/FI112079B/fi not_active IP Right Cessation
- 1997-01-27 NO NO970349A patent/NO308248B1/no not_active IP Right Cessation
-
2001
- 2001-12-05 CN CN01142735A patent/CN1394857A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0773943A1 (en) | 1997-05-21 |
AU697138B2 (en) | 1998-09-24 |
US5646141A (en) | 1997-07-08 |
AU3151795A (en) | 1996-02-22 |
US5608082A (en) | 1997-03-04 |
NO970349D0 (no) | 1997-01-27 |
DE69522945T2 (de) | 2002-03-28 |
NO970349L (no) | 1997-03-12 |
CA2195420A1 (en) | 1996-02-08 |
DK0773943T3 (da) | 2002-03-04 |
EP0773943B1 (en) | 2001-09-26 |
DE69522945D1 (de) | 2001-10-31 |
ATE206122T1 (de) | 2001-10-15 |
ES2162933T3 (es) | 2002-01-16 |
NZ290703A (en) | 1998-11-25 |
FI970317A (fi) | 1997-03-05 |
CN1394857A (zh) | 2003-02-05 |
FI970317A0 (fi) | 1997-01-24 |
CN1154110A (zh) | 1997-07-09 |
PT773943E (pt) | 2002-01-30 |
NO308248B1 (no) | 2000-08-21 |
SI0773943T1 (en) | 2001-12-31 |
CN1091770C (zh) | 2002-10-02 |
KR100380610B1 (ko) | 2003-08-27 |
RU2152945C2 (ru) | 2000-07-20 |
MX9700675A (es) | 1997-04-30 |
WO1996003406A1 (en) | 1996-02-08 |
FI112079B (fi) | 2003-10-31 |
JPH10503762A (ja) | 1998-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW432062B (en) | Compounds useful as antiproliferative agents and garet inhibitors | |
CN102460291B (zh) | 可变透光率滤光片及其应用 | |
US5500760A (en) | Electrochemichromic solutions, processes for preparing and using the same, and devices manufactured with the same | |
US5611966A (en) | Electrochemichromic solutions, processes for preparing and using the same, and devices manufacturing with the same | |
US7450291B2 (en) | Multi-cell electrochromic devices | |
TWI281054B (en) | Electrochromic device based on poly-(3,4-dioxy-thiophene)derivatives | |
CN105026146A (zh) | 具有作为导电层的低辐射(low-e)涂层的特性转换窗 | |
EP1812822A2 (en) | Electrochromic compounds and associated media and devices | |
JP4028134B2 (ja) | ポリ(3,4−エチレンジオキシチオフェン)誘導体に基づいたuv安定化電気着色性アセンブリ | |
WO2013054367A1 (en) | Electrochromic device | |
DE19824186A1 (de) | Elektrochrome Anordnung auf Basis von Poly-(3,4-ethylendioxy-thiophen)-Derivaten und Gel-Elektrolyt mit UV-Schutz | |
CN105807526A (zh) | 可在显示态和镜面态之间相互切换的显示装置 | |
WO2011096386A1 (ja) | 有機/金属ハイブリッドポリマーを使用したスマートウインドウ、スマートウインドウ製造方法、及びスマートウインドウシステム | |
EP1556733A1 (en) | Electrochromic devices having an electron shuttle | |
TWM432062U (en) | Electrochromic element | |
TW576938B (en) | Electrochromic assembly based on poly(3,4-ethylenedioxythiophene) derivatives in combination with a counterelectrode containing metal oxides from transition group VI or VIII | |
CN206870954U (zh) | 一种内后视镜及汽车 | |
Neshkovska | Multiple applications of electrochromic materials in the automotive industry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |